Vertex Pharmaceuticals Cystic Fibrosis Drug Gets Positive Opinion in EU For Treatment in Infants
By Adriano Marchese
Vertex Pharmaceuticals said Friday that its treatment for cystic fibrosis was given a positive opinion by European Union regulators to treat infants with specific mutations of the gene.
The pharmaceutical company said that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for the label expansion of the drug ivacaftor, also known as Kalydeco.
The approval is to expand the treatment of infants with cystic fibrosis between the ages of one to four months who have certain specific mutations of the cystic fibrosis transmembrane conductance regulator gene.
Kalydeco aims to treat the underlying cause of cystic fibrosis, a life-shortening genetic disease that affects the lungs, liver, pancreas, GI tract, sinuses, sweat glands and reproductive tract.
In the EU, the treatment is already approved to treat the disorder in patients aged four months and older.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
February 23, 2024 07:59 ET (12:59 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth